Purpose: Medulloblastoma (MB) and atypical teratoid/rhabdoid tumor (AT/RT) are common pediatric brain malignancies. Radiation carries high risks of developmental sequelae in young children, and current treatments remain inadequate. Viral gene therapy has safety concerns in pediatric patients, so a safe, effective nonviral polymeric nanoparticle system is needed for gene delivery to pediatric CNS tumors.
Hypothesis: If biodegradable poly(beta-amino ester) (PBAE) nanoparticles deliver plasmid DNA encoding the suicide gene herpes simplex virus type I thymidine kinase (HSVtk) to pediatric brain cancer cells, then transfected cells will undergo controlled apoptosis upon ganciclovir (GCV) treatment, and in vivo intracranial administration will prolong survival in orthotopic MB and AT/RT xenograft models.
Aims: Synthesize and characterize a library of PBAE polymers and nanoparticles for plasmid DNA delivery. - Screen formulations for transfection efficacy and cytotoxicity in pediatric MB and AT/RT cell lines. - Investigate cellular uptake and endocytosis pathways. - Evaluate HSVtk/GCV suicide gene therapy in vitro. - Test in vivo efficacy of PBAE-HSVtk nanoparticles delivered by convection-enhanced delivery (CED) in orthotopic xenograft mouse models.
Delivery system:
Component: Polymer class; Details: Poly(beta-amino ester)s (PBAEs), biodegradable cationic polymers
Component: Synthesis; Details: Michael addition of diacrylate “B” monomers (B4, B5) with amine “S” monomers (S3, S4, S5), end-capped with amine “E” monomers (E6, E7)
Component: Lead polymers; Details: 447 (B4-S4-E7) at 90 w/w for BT-12; 537 (B5-S3-E7) at 90 w/w for D425
Component: Payload; Details: Plasmid DNA: GFP reporter, HSVtk suicide gene, Cy5-labeled DNA for uptake
Component: Nanoparticle formation; Details: Electrostatic self-assembly in acidic buffer (25 mM NaAc, pH 5)
Component: Size / charge; Details: ~100–200 nm; slightly positive zeta potential
Component: Targeting ligand; Details: None
Component: Key feature; Details: Biodegradable esters, titratable tertiary amines for endosomal escape, cationic secondary amines for DNA complexation; lyophilized with sucrose for storage
Approach: In vitro: Human BT-12 AT/RT cells and D425 group 3 medulloblastoma cells. - Transfection: GFP reporter screening, flow cytometry, MTS viability; comparison with Lipofectamine 2000/3000 and 25 kDa branched PEI. - Uptake/endocytosis: Cy5-labeled DNA; inhibitors chlorpromazine (clathrin), methyl-β-cyclodextrin (lipid raft), genistein (caveolin), cytochalasin-D (macropinocytosis). - HSVtk/GCV killing: Transfection with HSVtk or GFP, GCV treatment on days 1, 3, 5; live/dead imaging on day 7. - In vivo: Athymic nude mice; intracranial BT-12 (5×10⁵) or D425 (1.25×10⁵) implantation; tumors formed 10 or 7 days; CED infusion of nanoparticles 3 times; daily intraperitoneal GCV; n = 10 per group (GFP nanoparticles, HSVtk nanoparticles, sham PBS); survival by Kaplan–Meier. - No immune-competent model; no human data.
Key methods: Polymer characterization: ¹H NMR, GPC. - Nanoparticle characterization: DLS, zeta potential, TEM. - Transfection / viability: Flow cytometry for GFP; MTS assay. - Uptake: Flow cytometry for Cy5-DNA. - Endocytosis pathway: Small-molecule inhibitors. - Cell killing: Hoechst 33342 / propidium iodide imaging and Cellomics analysis. - In vivo survival: Kaplan–Meier with Mantel–Cox log-rank test.
Key results: Transfection: Several PBAE formulations achieved >50% transfection in both BT-12 and D425 cells with low cytotoxicity. Optimized formulations significantly outperformed 25 kDa PEI and Lipofectamine 3000. - Uptake: 447 90 w/w and 537 90 w/w produced highest cellular uptake. Clathrin-mediated endocytosis was the major productive pathway; caveolin-mediated uptake was inefficient. - HSVtk/GCV killing: In BT-12 cells, HSVtk nanoparticles + GCV caused >65% cell death at all GCV doses; GFP/GCV controls showed no appreciable cytotoxicity. - In vivo survival: BT-12: median survival 35 days untreated → 42 days with HSVtk nanoparticles (20% longer; p = 0.0083). D425: median survival 19 days untreated → 31 days with HSVtk nanoparticles (63% longer; p < 0.0001). GFP nanoparticle groups tracked untreated controls. - Lyophilization: Lyophilized nanoparticles retained size, zeta potential, and in vitro transfection comparable to fresh nanoparticles.
Interpretation: The authors claim that biodegradable PBAE nanoparticles are a safe and effective nonviral nanomedicine for delivering suicide gene therapy to pediatric CNS malignancies. The data provide proof of principle that PBAE-HSVtk nanoparticles can induce tumor cell killing in vitro and significantly prolong survival in orthotopic MB and AT/RT xenograft models, offering a promising alternative to radiation and viral vectors.
Limitations: In vivo model: Athymic nude mouse xenografts only; no immune-competent or large-animal validation. - Small sample size: n = 10 per group. - No long-term toxicity or safety data. - Invasive delivery: CED requires intracranial administration; not a systemic delivery approach. - No targeting ligand: Delivery relies on local administration and passive tumor distribution. - Limited cell lines: Two pediatric CNS tumor lines only. - No direct comparison with clinical standard of care (e.g., radiation or systemic chemotherapy). - No biodistribution or clearance data. - No evaluation of repeat-dose safety or long-term expression. - Survival benefit, not cure: Median survival extended, but animals eventually succumbed. - No human translation data.
